Brookline Capital Markets Estimates Moderna FY2030 Earnings

Key Points

• Brookline Capital Markets lowered its FY2030 EPS forecast for Moderna to $18.19 from $19.11, while maintaining a “Buy” rating. This contrasts with the current-year consensus estimate of a $6.11 per-share loss.
• Moderna’s latest quarter exceeded expectations, reporting a $1.97 loss per share versus the projected $2.03 loss and revenue of $145 million versus the $102.93 million consensus. However, the company remained deeply unprofitable, with a negative 141.43% net margin.
• Analyst sentiment is mixed: Moderna has a consensus “Hold” rating, a $103.95 average price target, and 7 Buy, 14 Hold, and 4 Sell ratings. The stock opened at $200.10, well above its 200-day moving average of $97.30, reflecting substantial volatility and a sharp prior rally.

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Brookline Capital Markets decreased their FY2030 earnings per share (EPS) estimates for shares of Moderna in a report released on Thursday, October 22nd. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings of $18.19 per share for the year, down from their prior forecast of $19.11. Brookline Capital Markets has a "Buy" rating on the stock. The consensus estimate for Moderna's current full-year earnings is ($6.11) per share.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts' consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. During the same period in the prior year, the firm earned ($2.13) earnings per share. The firm's revenue for the quarter was up 2.1% compared to the same quarter last year.

A number of other research analysts have also weighed in on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Moderna in a report on Wednesday, September 9th. Rothschild & Co Redburn cut Moderna from a "neutral" rating to a "sell" rating and raised their price objective for the stock from $40.00 to $81.00 in a research note on Thursday, September 3rd. Wolfe Research raised Moderna from an "underperform" rating to a "peer perform" rating in a report on Tuesday, August 25th. JPMorgan Chase & Co. upped their target price on Moderna from $40.00 to $77.00 and gave the company an "underweight" rating in a research report on Friday, August 21st. Finally, The Goldman Sachs Group upped their target price on Moderna from $120.00 to $137.00 and gave the company a "neutral" rating in a research report on Thursday, October 15th. Seven investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, Moderna currently has an average rating of "Hold" and a consensus target price of $103.95.

Moderna Price Performance

MRNA stock opened at $200.10 on Monday. The stock has a market capitalization of $79.89 billion, a PE ratio of -25.04 and a beta of 1.09. Moderna has a 52 week low of $22.28 and a 52 week high of $254.48. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average of $172.79 and a 200 day moving average of $97.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Apollon Wealth Management LLC increased its holdings in Moderna by 13.6% in the 3rd quarter. Apollon Wealth Management LLC now owns 5,973 shares of the company's stock valued at $1,150,000 after purchasing an additional 713 shares during the last quarter. Aries Wealth Management purchased a new stake in Moderna in the third quarter valued at approximately $385,000. Kingswood Wealth Advisors LLC purchased a new stake in Moderna in the third quarter valued at approximately $348,000. Sigma Planning Corp purchased a new stake in Moderna in the third quarter valued at approximately $287,000. Finally, EULAV Asset Management acquired a new position in Moderna during the third quarter worth $1,873,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Insider Buying and Selling at Moderna

In related news, CFO Jamey Mock sold 34,836 shares of the firm's stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares of the company's stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the firm's stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the completion of the transaction, the president owned 1,525,858 shares in the company, valued at approximately $219,921,913.54. This trade represents a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 197,251 shares of company stock valued at $33,875,904 over the last ninety days. Corporate insiders own 10.80% of the company's stock.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported positive Phase 3 INTerpath-001 results for the personalized mRNA cancer vaccine, intismeran autogene, used with Keytruda. The treatment reduced the risk of melanoma recurrence or death by 42%, while also improving distant metastasis-free survival. Oncologists described the findings as a major advance in melanoma care. Nature article
• Positive Sentiment: The results strengthen the case for Moderna’s oncology pipeline and could support a major future revenue stream beyond COVID-19 vaccines, particularly if additional trials demonstrate benefits in other cancers. Moderna has also advanced its mRNA bird-flu vaccine into a late-stage trial, adding another potential pipeline catalyst. Bird flu vaccine trial article
• Neutral Sentiment: Moderna’s recent addition to the Nasdaq-100 and analyst support provide structural and sentiment benefits, but these factors have less immediate influence than the cancer-vaccine readout. The stock had already posted an exceptionally strong rally, leaving the valuation highly sensitive to new clinical information. Nasdaq-100 inclusion article
• Negative Sentiment: Partial trial data appeared on social media ahead of Moderna and Merck’s planned ESMO presentation, triggering extreme volatility and a sharp selloff. The premature release disrupted the expected news event and encouraged a “sell-the-news” reaction. CNBC data leak article
• Negative Sentiment: Although clinically meaningful, the 42% reduction fell short of the market’s very high expectations after Moderna’s dramatic run-up. Investors also questioned whether the results will translate beyond melanoma, how quickly the product could reach the market, and its eventual commercial opportunity. The breach of near-term technical support and heightened trading swings add further pressure. Zacks analysis

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company's research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.